

Comment on 'Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors'

M Singhera^{*1} and R Huddart²

¹Department of Urology, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Surrey, UK and ²Department of Radiotherapy, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Surrey, UK

Willemse *et al* (2013) recently reported their results regarding prevalence of metabolic syndrome and risk of cardiovascular disease (CVD) in survivors of testicular cancer who were treated with chemotherapy. This topic has particular relevance as cure rates are increasing across all cancer types due to increase in uptake of screening, better imaging modalities and effective treatments. However, we have certain reservations regarding the data presented and the conclusions drawn by the authors.

The authors do not report on the number of survivors who were on antihypertensive, lipid modifying and antidiabetic medication and whether those who were on these medications were excluded from the analysis in calculating the 10-year risk for CVD using the Framingham Risk Score (FRS) and Systemic Coronary Risk Examination (SCORE) predictive models. We assume that none of the controls were on cardiac-modifying drugs as the authors' state that controls were healthy men who were screened for CVD. If survivors on cardiac-modifying drugs were included in calculating the 10-year CVD risk, then there is a distinct possibility of diluting the calculated risk.

Furthermore, it appears rather contradictory that despite robust evidence that metabolic syndrome predisposes individuals to a nearly twofold risk of CVD (Gami *et al*, 2007), the results in the study do not support this. This may be explained by the small number of patients in the study (the authors do not describe any calculations as to how the study was powered) and also by the fact that actuarial analysis suggest that the risk of CVD in testicular cancer survivors only becomes apparent after 10 years or so (Huddart *et al*, 2003).

Additionally, the accuracy of risk prediction models such as FRS and SCORE in the younger population is debatable (Berry *et al*, 2007; Cavanaugh-Hussey *et al*, 2008; Cooney *et al*, 2010). Both FRS and SCORE models place emphasis on age to predict risk. Thus, notwithstanding their risk profile all young individuals will have a low absolute risk of CVD.

Perhaps a more pertinent analysis would be to derive lifetime risk rather than a 10-year risk for this cohort of survivors, as majority of these survivors are < 40 years of age at the completion of their treatment and the risk of CVD is most manifest beyond 50

years of age. Another option, which could be recommended for counselling survivors regarding the risk of CVD in survivorship clinics, would be the use of relative risk charts to predict risk (Graham *et al*, 2007).

In the discussion section, the authors state that 'most of the GCT survivors have long-term partial or complete hypogonadism'. There is conclusive evidence that demonstrates that approximately only 12–16% of survivors have complete hypogonadism (Huddart *et al*, 2005), the severity of which is expectedly associated with increased treatment burden, particularly chemotherapy. Three studies in GCT survivors (Nuver *et al*, 2005; Haugnes *et al*, 2007; de Haas *et al*, 2013) have previously demonstrated the association of hypogonadism and metabolic syndrome. Though we agree with the authors that follow-up guidelines should include assessment of lipid profile, blood pressure and gonadal function (van As *et al*, 2008), there is currently no evidence to support testosterone supplementation in those with testosterone levels in the lower range of normal. In the United Kingdom, we are currently recruiting patients into a double blind multi-centre placebo controlled trial (TRYMS) to assess the feasibility and effectiveness of testosterone replacement in those survivors who have a low-normal testosterone (7–12 nmol l⁻¹).

In conclusion, we acknowledge that the study by Willemse *et al* (2013) is topical and corroborates previous studies; however, we feel the authors' conclusion regarding cardiovascular risk is misleading. Large-scale longitudinal cohort studies of survivors, who are at high risk, are needed to accurately ascertain cardiovascular risk.

REFERENCES

- Berry JD, Lloyd-Jones DM, Garside DB, Greenland P (2007) Framingham risk score and prediction of coronary heart disease death in young men. *Am Heart J* 154: 80–86.

*Correspondence: M Singhera; E-mail: mausam.singhera@rmh.nhs.uk
Published online 17 September 2013



- Cavanaugh-Hussey MW, Berry JD, Lloyd-Jones DM (2008) Who exceeds ATP-III risk thresholds? Systematic examination of the effect of varying age and risk factor levels in the ATP-III risk assessment tool. *Prev Med* **47**: 619–623.
- Cooney MT, Dudina A, D'Aogstino R, Graham IM (2010) Cardiovascular risk-estimation systems in primary prevention: do they differ? Do they make a difference? Can we see the future? *Circulation* **122**: 300–310.
- de Haas EC, Altena R, Boezen HM, Zwart N, Smit AJ, Bakker JL, van Roon AM, Postma A, Wolffenbuttel BHR, Hoekstra HJ, van Leeuwen FE, Sleijfer DT, Gietema JA (2013) Early development of the metabolic syndrome after chemotherapy for testicular cancer. *Ann Oncol* **24**: 749–755.
- Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM (2007) Metabolic syndrome and the risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. *J Am Coll Cardiol* **49**: 403–414.
- Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C, Hoes A, Humphries S, Knapton M, Perk J, Priori SG, Pyorala K, Reiner Z, Ruijlo L, Sans-Menendez S, Op Reimer WS, Weissberg P, Wood D, Yarnell J, Zamorano JL, Walma E, Fitzgerald T, Cooney MT, Dudina A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Funck-Brentano C, Filippatos G, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Altiner A, Bonora E, Durrington PN, Fagard R, Giampaoli S, Hemingway H, Hakansson J, Kjeldsen SE, Larsen L, Mancina G, Manolis AJ, Orth-Gomer K, Pedersen T, Rayner M, Ryden L, Sammut M, Schneiderman N, Stalenhoef AF, Tokgozoglul, Wiklund O, Zampelas A (2007) European guidelines on cardiovascular disease prevention in clinical practice: full text: fourth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). *Eur J Cardiovasc Prev Rehabil* **14**(suppl 2): S1–S113.
- Haugnes HS, Aass N, Fossa SD, Dahl O, Klepp O, Wist EA, Svartberg J, Wilsgaard T, Bremnes RM (2007) Components of metabolic syndrome in long-term survivors of testicular cancer. *Ann Oncol* **18**: 241–248.
- Huddart RA, Norman A, Moynihan C, Horwich A, Parker C, Nicholls E, Dearnaley DP (2005) Fertility, gonadal and sexual function in survivors of testicular cancer. *Br J Cancer* **93**: 200–207.
- Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls I, Dearnaley DP (2003) Cardiovascular disease as a long-term complication of treatment of testicular cancer. *J Clin Oncol* **21**: 1513–1523.
- Nuver J, Smit AJ, Wolffenbuttel BHR, Sluiter J, Hoekstra HJ, Sleijfer DT, Gietema JA (2005) The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. *J Clin Oncol* **23**: 3718–3725.
- van As NJ, Gilbert DC, Money-Kyrle J, Bloomfield D, Beesley S, Dearnaley DP, Horwich A, Huddart RA (2008) Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse. *Br J Cancer* **98**: 1894–1902.
- Willemsse PM, Burggraaf J, Hamdy NAT, Weijl NI, Vossen CY, van Wulfen L, van Steijn-van Tol AQMJ, Rosendaal FR, Osanto S (2013) Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors. *Br J Cancer* **109**: 60–67.



This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/3.0/>

BJC

British Journal of Cancer (2013) 109, 2503–2504 | doi: 10.1038/bjc.2013.567

Reply: 'Comment on Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors'

P M Willemsse¹, J Burggraaf², N A T Hamdy³ and S Osanto^{*,1}

¹Department of Clinical Oncology, Leiden University Medical Center, Albinusdreef 2, 2333 Leiden, ZA, The Netherlands;

²Centre for Human Drug Research, Zernikedreef 10, 2333 Leiden, CL, The Netherlands and ³Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 Leiden, ZA, The Netherlands

We read with interest the Letter to the Editor by Singhera and Huddart (2013) and are pleased to respond to their comments.

Regarding their comments on missing data, the median follow-up time after completing treatment seems to have escaped their attention, as it was provided for all survivors and for separate treatment groups in Table 2 of our published article (Willemsse *et al.*, 2013).

We indeed had omitted to report on the actual number of survivors on antihypertensive, lipid modifying and/or antidiabetic medication, but did not exclude survivors on one or more of these medications from the analysis in calculating the 10-year risk of cardiovascular disease. In fact, the 36 survivors, with a median age of 50.7 years (range 29.5–69.5), who received cardiac-modifying medication had a Framingham Risk Score (FRS) and Systemic

*Correspondence: Professor S Osanto; E-mail: s.osanto@lumc.nl
Published online 17 September 2013

